Paris - Delayed Quote EUR

Biosynex SA (ALBIO.PA)

Compare
2.0450
-0.0550
(-2.62%)
At close: January 17 at 5:16:26 PM GMT+1
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
92,978.0000
92,978.0000
196,587.0000
382,532.7520
153,895.3730
Cost of Revenue
43,846.0000
43,846.0000
94,261.0000
176,118.7840
84,576.2110
Gross Profit
49,132.0000
49,132.0000
102,326.0000
206,413.9680
69,319.1620
Operating Expense
81,874.0000
81,874.0000
67,266.0000
65,295.5480
23,623.8250
Operating Income
-32,742.0000
-32,742.0000
35,060.0000
141,118.4200
45,695.3370
Net Non Operating Interest Income Expense
1,288.0000
1,288.0000
663.0000
94.9250
-224.6920
Pretax Income
-38,164.0000
-38,164.0000
29,804.0000
139,620.4860
44,370.0930
Tax Provision
-2,555.0000
-2,555.0000
8,571.0000
32,937.3510
12,149.8570
Net Income Common Stockholders
-36,946.0000
-36,946.0000
15,657.0000
104,004.4510
31,369.8250
Diluted NI Available to Com Stockholders
-36,946.0000
-36,946.0000
15,657.0000
104,004.4510
31,369.8250
Basic EPS
-3.45
--
1.53
10.08
3.52
Diluted EPS
-3.45
--
1.52
10.01
0.12
Basic Average Shares
10,708.9860
--
10,233.3330
10,317.9020
8,911.8820
Diluted Average Shares
10,708.9860
--
10,300.6580
10,390.0550
8,911.8820
Total Operating Income as Reported
-37,404.0000
-37,404.0000
38,883.0000
140,654.0590
45,734.5110
Total Expenses
125,720.0000
125,720.0000
161,527.0000
241,414.3320
108,200.0360
Net Income from Continuing & Discontinued Operation
-36,946.0000
-36,946.0000
15,657.0000
104,004.4510
31,369.8250
Normalized Income
-30,685.2205
-30,685.2205
19,873.8208
105,221.5445
32,169.0130
Interest Income
563.0000
563.0000
886.0000
57.8880
1.0660
Interest Expense
2,075.0000
2,075.0000
501.0000
346.7230
224.3180
Net Interest Income
1,288.0000
1,288.0000
663.0000
94.9250
-224.6920
EBIT
-36,089.0000
-36,089.0000
30,305.0000
139,967.2090
44,594.4110
EBITDA
-6,230.0000
-6,230.0000
51,669.0000
146,579.7240
51,841.7780
Reconciled Cost of Revenue
43,846.0000
43,846.0000
94,261.0000
176,118.7840
84,576.2110
Reconciled Depreciation
13,459.0000
13,459.0000
21,364.0000
2,038.9900
7,247.3670
Net Income from Continuing Operation Net Minority Interest
-36,946.0000
-36,946.0000
15,657.0000
104,004.4510
31,369.8250
Total Unusual Items Excluding Goodwill
-6,710.0000
-6,710.0000
-5,919.0000
-1,592.8590
-1,100.5520
Total Unusual Items
-6,710.0000
-6,710.0000
-5,919.0000
-1,592.8590
-1,100.5520
Normalized EBITDA
480.0000
480.0000
57,588.0000
148,172.5830
52,942.3300
Tax Rate for Calcs
0.0001
0.0001
0.0003
0.0002
0.0003
Tax Effect of Unusual Items
-449.2205
-449.2205
-1,702.1792
-375.7655
-301.3640
12/31/2020 - 3/28/2011

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALIMP.PA Implanet S.A.
0.1240
-3.50%
 
CEVI.ST CellaVision AB (publ)
227.00
+0.89%
 
GBT.PA Guerbet SA
26.70
+0.38%
 
ALSGD.PA SpineGuard SA
0.2130
-0.47%
 
ALMDT.PA Median Technologies SA
4.8000
-6.25%
 
ALNOV.PA Novacyt S.A.
0.6650
-5.94%
 
TRIB Trinity Biotech plc
0.8260
+0.67%
 
CTKB Cytek Biosciences, Inc.
5.46
-0.55%
 
QDEL QuidelOrtho Corporation
41.74
-0.33%